Melanoma cells can hide, but they can’t run from Eduardo Davila, PhD, associate director of cancer research training and education coordination at the University of Colorado Cancer Center.
Davila recently received a prestigious R01 grant from the National Cancer Institute to better understand why some melanoma patients don’t respond to immunotherapy, and if there are drugs doctors can prescribe to make those patients more able to respond to the therapy. The five-year grant could eventually lead to a Phase I clinical trial in patients with rare melanoma, which tends to be less responsive to immunotherapy.
We spoke with Davila about the research and its potential impacts.